
Christopher Rushton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/625434/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2019, 37, 190-201. | 0.8 | 257 |
| 2 | Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood, 2019, 134, 802-813. | 0.6 | 96 |
| 3 | The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood, 2019, 134, 1528-1532. | 0.6 | 82 |
| 4 | Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Advances, 2020, 4, 2886-2898. | 2.5 | 59 |
| 5 | TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nature Medicine, 2020, 26, 577-588. | 15.2 | 46 |
| 6 | Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood, 2020, 136, 572-584. | 0.6 | 44 |
| 7 | Characterization of DLBCL with a PMBL gene expression signature. Blood, 2021, 138, 136-148. | 0.6 | 19 |
| 8 | Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Reports, 2021, 37, 109817. | 2.9 | 14 |
| 9 | Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries. Methods in Molecular Biology, 2019, 1956, 383-435. | 0.4 | 9 |
| 10 | Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood Advances, 2021, 5, 2945-2957. | 2.5 | 7 |
| 11 | CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas. Blood, 2019, 134, 1608-1608. | 0.6 | 5 |
| 12 | PRPS-ST: A Protocol-Agnostic Self-training Method for Gene Expression–Based Classification of Blood Cancers. Blood Cancer Discovery, 2020, 1, 244-257. | 2.6 | 4 |
| 13 | Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP. Blood, 2019, 134, 921-921. | 0.6 | 2 |
| 14 | The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 8-9. | 0.6 | 1 |
| 15 | Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 31-31. | 0.6 | 1 |
| 16 | Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma. Blood, 2018, 132, 4610-4610. | 0.6 | 0 |
| 17 | Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma. Blood, 2019, 134, 1478-1478. | 0.6 | 0 |
| 18 | NFKBIZ3′ UTR Mutations Confer Selective Growth Advantage and Activate Genes with Therapeutic Implications in Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 296-296. | 0.6 | 0 |